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Abstract
Limb-Girdle Muscular Dystrophy type 2I (LGMD2I) is an inheritable autosomal, recessive disorder caused by mutations in the
FuKutin-Related Protein (FKRP) gene (FKRP) located on chromosome 19 (19q13.3). Mutations in FKRP are also associated
with Congenital Muscular Dystrophy (MDC1C), Walker-Warburg Syndrome (WWS) and Muscle Eye Brain disease (MEB). These
four disorders share in common an incomplete/aberrant O-glycosylation of the membrane/extracellular matrix (ECM)
protein a-dystroglycan. However, further knowledge on the FKRP structure and biological function is lacking, and its
intracellular location is controversial. Based on immunogold electron microscopy of human skeletal muscle sections we
demonstrate that FKRP co-localises with the middle-to-trans-Golgi marker MG160, between the myofibrils in human rectus
femoris muscle fibres. Chemical cross-linking experiments followed by pairwise yeast 2-hybrid experiments, and co-immune
precipitation, demonstrate that FKRP can exist as homodimers as well as in large multimeric protein complexes when
expressed in cell culture. The FKRP homodimer is kept together by a disulfide bridge provided by the most N-terminal
cysteine, Cys6. FKRP contains N-glycan of high mannose and/or hybrid type; however, FKRP N-glycosylation is not required
for FKRP homodimer or multimer formation. We propose a model for FKRP which is consistent with that of a Golgi resident
type II transmembrane protein.
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Introduction
Defects of a-dystroglycan (a-DG) O-glycosylation are asso-
ciated with several forms of inheritable muscular dystrophies
(Limb Girdle Muscular Dystrophy type 2I; LGMD2I), of which
some are congenital (Congenital Muscular Dystrophy type 1C;
MDC1C), and some are associated with brain (Fukyama
Congenital Muscular Dystrophy; FCMD, Walker-Warburg
Syndrome; WWS) and eye abnormalities (Muscle Eye Brain
disease; MEB) [1]. a-DG is a component of the dystrophin-
glycoprotein complex (DGC) and contains multiple sites for O-
linked glycosylation [2,3]. Proper O-glycosylation of a-DG is
crucial for its interaction with the extracellular laminin-a2a n d
a g r i ni nm u s c l e ,a n dn e u r e x i ni nb r a i n[ 4 , 5 , 6 ] .a-DG
hypoglycosylation precludes these interactions and the disrup-
tion of the link between these extracellular components and the
actin cytoskeleton, is thoughtt ob ep a r to ft h em o l e c u l a r
pathogenesis of the muscular dystrophy phenotype in LGMD2I
and the additional brain involvement seen in WWS and MEB
[7]. These disorders are collectively known as dystroglycano-
pathies, and they can be caused by mutations in any one of six
different genes encoding known or putative glycosyltransferases
or phosphotransferases. These genes are POMGnT1,e n c o d i n g
protein O-linked mannose ß-1,2-N acetylglucosaminyl-transfer-
ase 1 [8,9], POMT1 and POMT2 e n c o d i n gac o m p l e xt h a t
confers protein O-mannosyltransferase activity [10,11,12],
LARGE [13] likely to be involved in post-phosphoryl modifica-
tion of phosphorylated O-linked mannose [14], FKTN [15]
encoding fukutin, a putative phosphoryl ligand transferase [16]
and, finally, the fukutin related protein gene, FKRP [17,18],
encoding a 495 aa polypeptide (human FKRP; hFKRP) of
unknown function.
Mutations in FKRP were originally reported to cause MDC1C,
a severe form of congenital muscular dystrophy [17], however,
later it has become clear that mutations in the FKRP gene might
cause a wider range of phenotypes such as those of LGMD2I [18],
MEB [19] and WWS [20].
FKRP has been postulated to be involved in the O-
glycosylation of a-DG. This was based on the shift in a-DG
molecular weight and change in band intensity seen on Western
blots of muscle extracts from patients with MDC1C, using glycan
dependent anti a-DG antibodies [17]. Correspondingly, immune
histochemistry showed depletion of glycosylated a-DG in muscle
sections from LGMD2I patients when glycan specific a-DG
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directed towards the core protein were used [21]. FKRP and its
homologue Fukutin contain DXD motifs shared by some
glycosyltransferases [22]. However importantly, this family of
proteins also share sequence similarity with phosphoryl ligand
transferases [16,23].
Attempts to solve the intracellular localisation of FKRP have
produced contradicting results. Previous studies based on immune-
cytochemistry/-histochemistry on various types of cultured cells or
tissue sections, from human and rodent muscle, have indicated
localisation of FKRP to the endoplasmic reticulum (ER) [24,25],
the Golgi apparatus [26,27,28,29,30] and the muscle cell
sarcolemma [31].
In this work, by employing high resolution immunogold
electron microscopy, we demonstrate that FKRP co-localises
with the middle-to-trans Golgi marker MG160, between the
myofibrils, in human rectus femoris muscle fibres. Furthermore, we
demonstrate that FKRP can interact with itself in living cells and
that FKRP can exist as a homodimer and in multimeric protein
complexes. FKRP homodimer formation depends on an N-
terminal interaction interface at which the dimers are covalently
linked by a disulfide bridge provided by Cys6, preceding a
putative N-terminal trans-membrane sequence motif. FKRP
contains two putative N-glycosylation sites. Both are occupied
with high mannose/hybrid type of oligosaccharides. However, N-
glycosylation is not required for FKRP homodimer or multimer
formation.
Results
FKRP co-localises with the Golgi marker MG160, between
the myofibrils of human skeletal muscle fibres
To investigate the in vivo localisation of endogenous FKRP in
muscle cells, separate double immunogold labelling experiments
were performed on human rectus femoris longitudinal sections, using
antibodies against FKRP and protein markers specifying either the
sarcolemma (anti ß-dystroglycan), Golgi (anti MG160) or endo-
plasmic reticulum (ER) (anti PDI). Overall, the 5 nm gold
particles, specific to FKRP, clustered (2–15 grains) at discrete
locations in the myofibrillar core, mainly between the myofibrils
(Fig. 1 A, B). Five-nm particles were associated with vesicle- or
cisternae-like structures and often they were found in close
proximity with mitochondria. Their locations were distinctly
different from those of ß-dystroglycan specific 10 nm gold particles
which were found to be scattered continuously along the muscle
cell membrane (Fig. 1C). Similar to signals specific to FKRP, PDI
specific signals were detected mainly between myofibrils but they
were also frequently associated with terminal sarcoplasmic
reticulum (SR) cisternae, neighbouring T-tubule like structures
(Fig. 1 D). However, FKRP and PDI specific signals were usually
not associated, but rather they appeared as spatially separated
clusters of 5 nm and 10 nm particles, respectively. In contrast,
FKRP specific 5 nm particles co-localised and, in fact, overlapped
with clusters of 10 nm particles specific to the Golgi marker
MG160 (Fig. 1A and B). The MG160 marker was previously
Figure 1. FKRP subcellular localisation in skeletal muscle, determined by double EM immunogold labelling. FKRP was detected with a
mixture of FKRP207 and FKRP208 primary antibodies followed by labelling with goat anti-rabbit antibody, conjugated with 5 nm gold particles (A, B,
C and D). Subcellular marker antibodies were, anti MG160 (Golgi) (A, B), anti ß-dys (sarcolemma) (C) and anti PDI (endoplasmic reticulum) (D).
Secondary antibody for detection of subcellular marker proteins was goat anti-mouse antibody, conjugated with 10 nm gold particles. Selected areas
(framed) were enlarged by 200%.
doi:10.1371/journal.pone.0022968.g001
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complex in soleus muscle cells of adult rats [32]. No co-localisation
of 5 nm and 10 nm particles was observed when omitting one of
the primary antibodies, in a series of control experiments as
explained in the Materials and Methods. Hence, we conclude that
the Golgi middle-to-trans cisterna is the location of FKRP in
human adult rectus femoris muscle cells.
FKRP is part of multimeric complexes that are sensitive to
reduction by DTT
Western blot analysis of lysates from FKRP expressing cells,
performed under reducing conditions, revealed a prominent
FKRP specific band migrating as the size of a monomer
(,58 kDa), as well as an additional band (,116 kDa) of lower
intensity, approximately twice the size as that expected for the
FKRP monomer (Fig. 2A, lanes 2 and 3). Discrete bands of higher
molecular weight were also observed. Under non-reducing
conditions an additional smeared higher molecular weight band
ranging from ,120 to ,220 kDa as well as a distinct band of
.,450 kDa were detected (Fig. 2A, lane 1). The involvement of
FKRP in these high molecular weight structures was further
investigated by adding the cross-linker Ethylene glycol-bis(Succi-
nimidylSuccinate) (EGS) immediately after cell lysis. EGS is a
homobifunctional, DTT insensitive, protein cross-linker with a
spacer arm of 16.1 A ˚ that can covalently link interacting proteins.
As shown in Figure 2B, upon cross-linking the FKRP monomer
disappeared and only higher molecular weight bands could be
detected. Distinct protein bands appeared at ,116 kDa and
,170–180 kDa and a smear of bands ranging in molecular
weights from 180 kDa to several hundred kDa were observed.
We conclude that FKRP is part of larger multimeric protein
complexes that range in size from the molecular weight of a dimer
to several hundred kDa. Some of these complexes are sensitive to
reduction by DTT and, accordingly, their components are likely
linked by disulfide bridges (Fig. 2A and B).
FKRP interacts with itself in living cells
The presence of a ,116 kDa band per se is suggestive but not
evidence of an FKRP dimer. The ,116 kDa band as well as
higher molecular weight protein bands might reflect covalent
interactions of FKRP with other proteins. Therefore, we
investigated if FKRP had the capacity to interact with itself in a
pairwise yeast two-hybrid experiment followed by a co-immune
precipitation (Co-IP) experiment.
The coding sequence for amino acids 32-494 of human FKRP
was cloned into the bait vector pB27 in-frame with the coding
sequence of LexA DNA binding domain (DBD): (pP27 (N-LexA-
FKRP32-494-C)) and into the pray vector, p7, in frame with the
Gal4 activation domain (AD) (pP7 (N-GAL4 -FKRP32-494-C)).
Diploid yeast cells containing both bait and prey expression
constructs were spotted onto non-selective and selective media
along with appropriate controls, as explained in the Materials and
Methods. As displayed in the left panel of Figure 3A, the control
experiment demonstrated that all clones tested contained both the
prey and bait vector, a requirement for growth on media lacking
Leu and Trp (DO-2). However, only FKRP32-494 in bait-prey
combination allowed growth on triple minus medium (DO-3)
selecting for expression of the HIS3 reporter gene (Fig. 3A, right
panel). This result demonstrates that FKRP32-494 self-interaction
can take place in yeast cells.
To examine if the FKRP-FKRP interaction, detected by cell
growth in yeast two-hybrid assays, also occurs in mammalian cells
we co-expressed full length FKRP, C-terminally tagged with HA
(FKRP-HA) and Myc (FKRP-Myc) epitopes, in COS-7 cells. The
cell lysates were prepared in the presence of 5 mM N-
ethylmaleimide (NEM); an SH-group alkylating agent which
modifies free SH groups of cysteines and prevents aberrant post-
lysis SH-mediated protein association.
As seen in Figure 3B, FKRP-HA was co-precipitated with anti
Myc antibodies, but only from a lysate originating from cells co-
transfected with both FKRP-HA and FKRP-Myc expressing
plasmids. FKRP-HA was not co-precipitated with FKRP-Myc
from a mixture of lysates originating from separate solo
transfections of FKRP-HA and FKRP-Myc carrying expression
plasmids. This result demonstrates that FKRP self interaction can
take place in vivo, in mammalian cells.
The two FKRP N-glycosylation sites are occupied with
high mannose and/or hybrid oligosaccharides
Based on its primary amino acid sequence, human FKRP has a
predicted molecular weight of 54.6 kDa (http://www.scripps.edu/
,cdputnam/protcalc.html). However, initial Western blot analysis
demonstrated a molecular weight of ,58 kDa both under non-
reducing and reducing conditions (Fig. 2A). This suggested that
FKRP contains a post-translational modification of approximately
3.5 kDa. Human FKRP (as well as FKRP from any other species
known) contains two putative N-glycosylation sites; AsnValSer
Figure 2. Recombinant FKRP forms multimers in mammalian
cells. COS-7 and BHK-21 cells were transfected with pcDNA3.1-FKRP or
empty vector (pcDNA3.1). Forty-eight hrs after transfection cells were
solubilised in lysis buffer with protease inhibitor. A) The cleared COS-7
lysate was either kept untreated (lane 1) or reduced with 400 mM DTT
at RT for 30 min (lane 2) or Sample Reducing agent at 99uC for 5 min
(lanes 3 and 4) and subsequently subjected to (4–12%) SDS-PAGE and
Western blot analysis. Lanes 1–3: lysates from pcDNA3.1-FKRP
transfections. Lane 4: lysate from pcDNA3.1 transfection serving as
negative control. B) A cleared BHK-21 lysate was treated with 10 mM
EGS at RT for 30 min and quenched with 35 mM Tris, pH 7.5 for 15 min.
The EGS treated sample and the accompanying untreated control
sample were reduced with Sample Reducing agent at 99uC for 5 min
and subjected to SDS-PAGE and Western blot analysis. In the above
experiments FKRP was detected using FKRP207 antibodies. MWM is
molecular weight marker.
doi:10.1371/journal.pone.0022968.g002
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bait construct, pB27-FKRP (N-LexA-FKRP32-494-C), and prey construct, pP7-FKRP (N-GAL4-FKRP32-494-C), were obtained by mating and spotted, at
the dilutions indicated, onto non-selective media lacking Trp and Leu (left panel) and selective media lacking Trp, Leu and His (right panel). Negative
controls contained empty bait and pray vectors, pB27 and pP7, or pB27 and pP7 in combination with prey and bait constructs, respectively. Positive
control (C+) contained human SMAD3 as bait (GI:5174512) and Human SMURF1 as prey (GI:31317291) as explained in Materials and Methods. B) Anti-
Myc antibody was employed to precipitate FKRP-Myc fusion proteins from COS-7 cell lysates. The lysates were prepared by pcDNA3.1-FKRP-Myc/
pcDNA3.1-FKRP-HA co-transfection (Cotr) or solo transfections of pcDNA3.1-FKRP-Myc and pcDNA3.1-FKRP-HA. An additional sample was prepared
by mixing pcDNA3.1-FKRP-Myc and pcDNA3.1-FKRP-HA lysates followed by incubation at RT for 30 min (Mix). All cell lysates used for Co-IP were
prepared in the presence of 5 mM NEM. Lysates from pcDNA3.1 and pcDNA3.1-FKRP-HA solo transfections served as negative controls whereas
lysates from pcDNA3.1-Myc transfected cells served as positive control for anti-Myc based immune precipitation. Input samples and precipitates were
subjected to (4–12%) SDS-PAGE, under reducing conditions, followed by Western blot analysis. On separate blots FKRP-Myc and FKRP-HA were
detected with anti-Myc and anti-HA antibodies, respectively. To asses the stringency of the of the Co-IP experiment, one of the blots (anti-HA) was
stripped and assayed for endogenous MAPK with anti-MAPK antibody (lower panel).
doi:10.1371/journal.pone.0022968.g003
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(hFKRP), respectively. In order to assess the composition of the
FKRP modification, protein lysates obtained from BHK-21 cells
transfected with human FKRP expressing plasmid, were treated
separately with the N-glycan specific glycosidases, PNGase F and
Endo H. Both PNGase F and Endo H treatment created a shift in
the molecular weight of FKRP, corresponding to ,3.5 kDa
(Fig. 4A), equivalent to the expected molecular weight of two N-
linked glycans. A similar experiment using lysates from transfected
COS-7 cells gave identical results (not shown). This demonstrates
that upon ectopic FKRP expression in BHK-21 and COS-7 cells,
both N-glycosylation sites are occupied with N-linked glycans.
Furthermore, since these glycans are sensitive to Endo H digestion
they must be composed of high mannose and/or hybrid type
oligosaccharides.
FKRP self interaction does not depend on N-glycosylation
To examine if FKRP self interaction is dependent on N-
glycosylation the two FKRP N-glycosylation sites were altered by
replacing asparagines (N, Asn) at amino acid positions 172 and
209 with glutamines (Q, Gln). By in vitro mutagenesis three mutant
pcDNA3.1-FKRP expressing constructs were made; FKRP-
Asn172Gln, FKRP-Asn209Gln and double mutant FKRP-
Asn172Gln/Asn209Gln. Mutant constructs were transfected into
COS-7 cells and the resulting lysates were prepared in the
presence of 5 mM NEM. The lysates were subjected to Western
blot analysis both under non-reducing as well as under reducing
conditions. As shown in Figure 4B, removal of both N-
glycosylation sites created shifts in the FKRP molecular weight
corresponding to what was seen in de-glycosylation experiments,
using PNGase F and Endo H (Fig. 4A). Hence, these results
confirm that recombinant FKRP is indeed occupied by two N-
glycans. Furthermore, the corresponding molecular weight
reduction of ,7 kDa for the ,116 kDa band is consistent with
the above conclusion that FKRP is forming a homodimer.
Removal of the FKRP N-glycosylation sites did not affect the
capacity of FKRP to form dimers and multimers (Fig. 4B). Thus,
we conclude that FKRP dimer and multimer formation is
independent of N-glycosylation.
FKRP-FKRP dimer formation depends on an N-terminal
interaction interface and a Cys6-Cys6 disulfide linkage
In order to identify the FKRP-FKRP interaction interface we
constructed C-terminal truncation mutants of FKRP: FKRP-373,
FKRP-282 and FKRP-157 (Fig. 5A) of which the numbers denote
the positions of the last amino acids in the truncated FKRP
polypeptides. pcDNA3.1-FKRP truncation clones were expressed
in COS-7 cells and the resulting lysates were prepared in the
presence of 5 mM NEM and subsequently subjected to Western
blot analysis. As shown in Figure 5B, FKRP truncation clones
were expressed at levels comparable to that of full length FKRP,
except FKRP-157 which repeatedly showed somewhat reduced
expression levels. All FKRP truncation mutants, even FKRP-157,
retained the property of forming dimers. However, in contrast to
FKRP-157, full length FKRP, FKRP-282 and FKRP-373 also
produced additional bands seen as smears under non-reducing
conditions and distinct high MW bands under reducing condi-
tions. These bands represent multimeric, FKRP containing,
protein complexes (Fig. 5B). Together, these results indicate that
the interaction interface responsible for homodimer formation, is
located in the N-terminal one third of FKRP and, furthermore,
that FKRP multimer formation depends on additional protein
segments that extend beyond residue 157 and into the C-terminal
two third of the FKRP polypeptide.
Figure 4. FKRP dimer and multimer formation is not dependent
on N-glycosylation. Cells were transfected with pcDNA 3.1-FKRP.
Forty-eight hrs after transfection cells were solubilised in lysis buffer
with protease inhibitor. A) A cleared BHK-21 lysate was treated with
either PNGase F or Endo H as explained in Materials and Methods and
subjected to (4–12%) SDS-PAGE under reducing conditions, followed by
Western blot analysis. An untreated sample served as control. B) COS-7
cells were transfected with mutant pcDNA3.1-FKRP constructs, in which
either one or both asparagines (Asn) involved in N-glycosylation had
been replaced with glutamine (Gln). The lysates were prepared in the
presence of 5 mM NEM and subjected to either non-reducing (left
panel) or reducing SDS-PAGE (330 mM DTT, RT for 30 min) (right panel),
followed by Western blot analysis. Antibody FKRP207 was used for the
detection of FKRP in these experiments.
doi:10.1371/journal.pone.0022968.g004
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located at amino acid residues 6, 168, 191, 289, 296, 317, 318 and
375. To examine the role of these cysteines in the formation of
FKRP dimers and multimers, cysteine (Cys, C) to serine (Ser, S)
substitutions were introduced to FKRP by in vitro mutagenesis
(Fig. 5A). Transfected COS-7 cells were lysed with lysis buffer
containing 5 mM NEM and subjected to Western blot analysis
under both protein non-reducing and reducing conditions. Cys to
Ser substitutions did not affect FKRP expression levels in COS-7
cells (Fig. 5C).
As displayed in Figure 5C, under both non-reducing and
reducing conditions, the mutant FKRP-Cys6Ser behaved distinct-
Figure 5. FKRP homodimer formation depends on a Cys6-Cys6 disulfide bridge. A) Schematic presentation FKRP C-terminal deletion
constructs. FKRP-373, FKRP-282 and FKRP-157 denote the length (aa) of the mutant construct. Red vertical bars show Cys (C) positions whereas yellow
vertical bars indicate the positions of putative N-glycosylation sites Asn-X-Thr/Ser (N-X-T/S). In the following experiments COS-7 cells were transfected
with various pcDNA3.1 constructs and cleared lysates were prepared 48 hrs post transfection in the presence of 5 mM NEM. In all these experiments
FKRP was detected with primary antibody FKRP207. B) Cleared lysates from FKRP C-terminal deletion mutants were either left untreated or subjected
to reduction (400 mM DTT, at RT for 30 min), followed by (4–12%) SDS-PAGE and Western blot analysis. C) Cleared lysates from FKRP CysRSer
substitution mutants were either left untreated (left panel) or subjected to reduction (400 mM DTT, at RT, for 30 min) (right panel), followed by (4–
12%) SDS-PAGE and Western blot analysis. Differences in migration between monomeric forms as well as between dimeric forms (5C) likely represent
different FKRP conformations resolved by SDS-PAGE. Such conformational differences might be induced by CysRSer mutations as some of the
mutant Cys residues must be expected to be involved in intra-molecular disulfide bridges. D) COS-7 lysates from deletion construct FKRP-157, and the
Cys6Ser mutant thereof, were subjected to SDS-PAGE under non-reducing conditions, followed by Western blot analysis.
doi:10.1371/journal.pone.0022968.g005
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CysRSer mutants. Under non-reducing conditions FKRP-Cys6-
Ser expressed only the ,58 kDa monomer as well as a strong
band of very high molecular weight (.500 kDa). In contrast, the
wild type FKRP and the other FKRPCys-Ser mutants expressed
both monomers (albeit FKRP-Cys289Ser only weakly) and dimers
of ,116 kDa, as well as smeared bands ranging in molecular
weights from ,180 kDa to several hundred kDas (Fig. 5C, left
panel). Furthermore, as the only mutant, FKRP-Cys6Ser
expressed exclusively FKRP monomers under reducing condi-
tions. For wild type FKRP, as well as for other FKRP CysRSer
mutants, the relative amount of monomer increased at the expense
of higher order multimers. However, in contrast to FKRP-
Cys6Ser, distinct bands corresponding to ,116 kDa and
,180 kDa were clearly visible (Fig. 5C, right panel).
In summary; as the only mutant, FKRP-Cys6Ser failed to
express the FKRP homodimer band of ,116 kDa under non-
reducing, as well as under reducing conditions. Hence, we
conclude that the FKRP homodimer is kept together by an
intermolecular disulfide bridge provided by Cys6 (Cys6-Cys6).
The role of Cys6 in dimer formation was confirmed by the
observation that FKRP-157-Cys6Ser, but not FKRP-157, failed to
form dimers, even under non-reducing conditions (Fig. 5D).
The involvement of other cysteines in FKRP dimer formation
was not evident; however, their participation in high molecular
weight structures is very likely since higher order multimers, above
180 kDa, were clearly sensitive to reduction by DTT (Fig. 5C).
Their composition and the role of FKRP in these larger protein
complexes remain to be investigated.
Discussion
FKRP subcellular localisation in muscle cells
Previous attempts to determine the intracellular localisation of
both endogenous and recombinant FKRP have been carried out
using immune cytochemistry on transfected cells and immune
histochemistry on tissue sections from heart or skeletal muscle
[24,25,26,27,28,29,30,31]. General problems in protein localisa-
tion studies are mislocalisation, because of protein over-production
in transfected cells, and/or lack of sensitivity or sufficient
microscopic resolution when studying complex cell types such as
those of skeletal muscle. This prompted us to assess endogenous
muscle FKRP localisation at maximum resolution using immu-
noelectron microscopy on ultrathin sections of human rectus femoris
muscle. A mixture of two polyclonal anti-FKRP antibodies,
corresponding both to the N-terminal region and the C-terminal
region of the FKRP polypeptide, showed co-localisation and
overlap with the Golgi marker MG160, between myofibrils, in
human skeletal muscle fibres. Perinuclear localisation, or co-
localisation with ER-lumen marker, PDI, or sarcolemma marker,
b-dystroglycan, was excluded. Hence, in accordance with the
location of MG160 [32] these results provide ultra structural
evidence for FKRP localisation in the middle-to-trans-cisternae of
the Golgi complex.
Some of the previous attempts to identify the intracellular
localisation of FKRP have been based on immune cytochemistry
on transfected cell lines of various origins. In this regard the Golgi
localisation of endogenous FKRP reported here is in accordance
with the findings of Esapa et al (2002 and 2005) [26,27],
Keramaris-Vrantsis et al (2007) [29] and Lu et al (2010) [30],
however, they conflict the findings of Matsumoto et al (2004) [24]
who found ectopically expressed FKRP to be located in ER.
Previous attempts to localise endogenous FKRP in muscle have
also generated conflicting results. Based on immunohistochemistry
on human muscle sections using the same antibody as Matsumoto
et al (2004) [24], Torelli et al (2005) [25] and Dolatshad et al (2005)
[28] found FKRP to have peri-nuclear localisation. These findings
are contrasting our results (this work) as well as the findings of
Beedle et al (2007) [31] who demonstrated FKRP localisation in
the sarcolemma on immunohistochemical sections of mouse
muscle cells. Muscle is a heterogeneous tissue and great variation
in cellular abundances and distribution patterns of organelles,
including the Golgi complex, have been reported; this particularly
in relation to fiber-type [32]. Nevertheless, the discrepant results
on FKRP intracellular localisation are very intriguing. None of
these reports should be disregarded, but rather they should
encourage further experiments, using a battery of validated anti
FKRP antibodies, to determine whether endogenous FKRP really
can exist in the three subcellular muscle cell locations reported
until to date; perinucleus [25,28], sarcolemma [31] and Golgi
cisternae (this work).
FKRP as a homodimer
Several lines of evidence based on non-reducing Western blot
analysis, protein cross-linking, pairwise yeast two-hybrid assays
and co-immune precipitation (Fig. 2 and 3) demonstrated FKRP-
FKRP self-interaction. Interestingly in this respect, whereas
FKRP-HA could be co-precipitated with FKRP-Myc from cellular
lysates originating from co-transfection experiments, FKRP-HA
could not be co-precipitated with FKRP-Myc from a mixture of
cellular lysates originating from separate solo transfections with
FKRP-HA and FKRP-Myc carrying expression plasmids. This
shows that when FKRP-FKRP assembly is once completed in the
cellular compartment further FKRP assembly is disallowed;
indicating that FKRP-FKRP assembly is a self limiting process
that is likely terminated by stoichiometric and steric constrictions
such as the complete occupation of interaction interfaces and
cysteine residues for possible disulfide bridge formation. Since the
FKRP homodimer was clearly sensitive to reduction by DTT, we
explored the role of its eight cysteines in dimer formation by
substituting them with serine. Replacement of Cys6, but none of
the seven other cysteines, disrupted FKRP dimerisation. We
conclude, therefore, that FKRP dimers are covalently connected
at Cys6, by disulfide linkage.
Important in this respect is that FKRP-FKRP association can
take place regardless of the presence of Cys6, but rather through
non-covalent interaction as shown in yeast cells. The FKRP
constructs used in yeast two-hybrid experiments were devoid of
residues 1–31, yet they demonstrated association allowing growth
on selective medium. Together with the fact that the severely
truncated FKRP-157 construct maintained the property to
dimerise, these results strongly indicate that an interaction
interface, necessary and sufficient for FKRP homodimer forma-
tion, is extending beyond residue 31 and into the N-terminal one
third of FKRP polypeptide.
By necessity, since the covalent disulfide bridge is provided by
Cys6 alone, the interaction interfaces, as well as the homodimer as
a whole, must display two-fold symmetry. Thus, a model can be
envisioned in which FKRP homodimerisation is initiated and
driven by hydrophobic interactions of which the resulting dimer is
subsequently stabilised by a Cys6-Cys6 disulfide bridge.
Recently Lu et al (2010) [30] demonstrated N-glycosylation of
recombinant FKRP expressed in Chinese Hamster Ovary (CHO)
cells. Here we show that both FKRP N-glycosylation sites are
occupied and that these glycans are composed of high mannose
and/or hybrid oligosaccharides. Furthermore, FKRP N-glycosyl-
ation is not required for homodimer or multimer formation.
However, it remains unknown whether the N-glycans are
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FKRP in multimeric complexes
Western blot analysis under protein non-reducing conditions, as
well as upon chemical protein cross-linking, showed that FKRP
also exists in higher order multimeric complexes. Further
dissection of the FKRP-FKRP interaction revealed that whereas
the most severely truncated mutant, FKRP-157, devoid of amino
acid residues 158–495, displayed no visible multimers, but
monomers and dimers only, the two less severely, C-terminally
truncated FKRP mutants, FKRP-373 and FKRP-282, maintained
the property to express not only monomers and dimers, but clearly
also large multimeric complexes. This indicates that whereas the
primary FKRP-FKRP dimer interaction interface is located in the
N-terminal one-third (1–157), the FKRP involvement in multimer
formation must be dependent on amino acid residues belonging to
the C-terminal two third - extending from residue 158 and
throughout the FKRP polypeptide. Since also large protein
complexes (.,180 kDa) appear to be sensitive to reduction by
DTT it is highly likely that other FKRP Cys residues are involved
in multimer formation. However, the complex multimer band
patterns from the experiments presented here (Fig. 2, 4 and 5) does
not allow such Cys residues to be identified at this juncture.
Notably however, at reducing conditions we have repeatedly
detected a weak, but distinct, FKRP specific band migrating as
,170–180 kDa, which disappeared along with the FKRP dimer
band of the FKRP-Cys6 mutant (Fig. 2A, 4B and 5C). This
suggests that the formation of the ,170–180 kDa complex
depends on a preceding covalent FKRP dimer formation. A
strong band of similar molecular weight appeared upon cross-
linking with EGS (Fig. 2B). The approximate molecular weight is
as expected for a putative FKRP homotrimer (Fig. 4B and 5C). A
disulfide-linked FKRP trimer would require the involvement of
more than one Cys residue. Therefore, the possible association of
an FKRP homodimer with yet a third FKRP polypeptide would
have to involve a non-covalent interaction. The composition of
multimers, ranging in molecular weight from that of a putative
FKRP trimer (,175 kDa) to several hundred kDas (Fig. 2A and
B), likely consist of both homo- and hetero-oligomeric proteins
complexes. Their compositions and role in FKRP function remain
to be explored.
FKRP localisation and structure is consistent with Golgi
resident type II transmembrane proteins
The Golgi apparatus is indeed a location that would be
expected for an enzyme involved in de novo O-glycan synthesis
and/or modification. Based on hydrophobicity plots and second-
ary structure analysis, FKRP was predicted to be a type II
transmembrane protein [26]. Most of the knowledge on type II
transmembrane proteins has been obtained from studies of N-
glycosyltransferases and sulfotransferases. In general Golgi resident
type II transmembrane proteins contain a short, cytoplasmically
exposed, amino-terminal domain followed by a transmembrane
domain, a stem region and a large, globular, catalytic domain
facing the luminal side [33,34]. Furthermore, they are known to
form homodimers and heterodimers, as well as homo- and hetero-
oligomeric protein complexes with other Golgi resident proteins
which function in the same biosynthetic pathway [35,36,37,38].
Accordingly, a model can be envisioned in which the N-terminal
transmembrane domains of an FKRP homodimer extend through
the Golgi membrane, forming a stabilising Cys6-Cys6 disulfide
bond at the cytoplasmic face. A proposed model for the FKRP
dimer is depicted in Figure 6.
Interestingly, although its biological significance is yet to be
explored, Lu et al (2010) [30] demonstrated that recombinant
FKRP can be secreted from CHO cells but, in contrast to the
putative dimer which was retained in the cell pellet, it was secreted
into the supernatant only as a monomer. This monomeric form
was presumably devoid of the putative 27 amino acid signal
peptide [30]. For such a phenomenon to occur FKRP must be
proteolytically cleaved, N-terminally, close to the membrane at the
luminal face, releasing FKRP from its N-terminal signal peptide.
Thus, their observations do not conflict with our model, but rather
they support our finding that Cys6 is the only contributor to a
covalent, symmetric, FKRP homodimeric interaction.
In summary, the FKRP localisation and intermolecular
interaction determined in this work is consistent with that of a
Golgi resident type II transmembrane protein. In the Golgi
cisternae FKRP and putative interacting partners will be
positioned to modify, or assist the modification of dystroglycan
as it passes, en route, to the plasma membrane. However, more
experiments are required to identify the FKRP substrate (if any)
and, moreover, whether FKRP has the capacity to invoke the
modification of other proteins besides dystroglycan.
Materials and Methods
Human specimens
Ethics Statement: An anonymous human rectus femoris control
specimen was provided by the Department of Pathology,
University Hospital of North-Norway. The use of this anonymous
muscle specimen, for immune electron microscopy, was approved
by The Regional Committee for Medical Research Ethics (REK
nord). With authorisation in the ACT 2008-06-20 no. 44: the
Figure 6. Proposed model of the Golgi resident FKRP dimer; a
putative glycosyltransferase. According to the type II transmem-
brane glycosyltransferase model, the architecture comprises a globular
catalytic domain, a stem region, a single pass transmembrane domain
and a cytoplasmic N-terminal tail [33,34,37]. Based on the present work
we suggest that FKRP forms homodimers via an interaction interface
that extends through the stem region. The interaction is stabilised by a
Cys6-Cys6 disulfide bridge in the N-terminal cytoplasmic tail resulting in
a covalently connected FKRP dimer with two-fold symmetry. The
catalytic domain is likely to interact with other proteins forming large
multimeric structures (not depicted). -S-S-; disulfide bridge, Y; N-glycan
of high mannose and/or hybrid type.
doi:10.1371/journal.pone.0022968.g006
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Antibodies
Anti-FKRP antibodies used for Western blot analyses and/or
immune electron microscopy were polyclonal rabbit anti-FKRP
antibodies generated against synthetic peptides FKRP107-122:
ALDRPAAASRPETYVA, and FKRP425-439: CGVMTKDTWLD
HRQDV, according to the double XP program of Eurogentec, Liege,
Belgium, and named FKRP207 and FKRP208, respectively. Both
antibodies were affinity purified against their corresponding peptide
antigens.
Rabbit polyclonal antibodies for the detection of HA (ab13834)
and Myc (ab9106) fusion tags were purchased from Abcam, UK.
Mouse monoclonal anti-MAP kinase 2 antibody (Erk2 clone
1B3B9) (Upstate/Chemicon, USA), was used as control to assess
the stringency in co-immune precipitation (CO-IP) experiments.
Secondary antibodies used in Western blot analysis were all
conjugated with alkaline phosphatase (AP); these were chicken
anti-rabbit antibodies (sc-2967) (Santa Cruz Biotechnology Inc.,
USA) and rabbit anti-mouse antibodies (Cat No. 81-6722)
(Invitrogen, USA).
In immunoelectron microscopy, monoclonal mouse anti-
MG160 Golgi complex antibody (AE-6) (ab58826) (Abcam,
UK), monoclonal mouse anti-ß-dystroglycan (ß-dys) antibody,
(7D11) (sc-33701) (Santa Cruz Biotechnology, USA), and mouse
anti- Protein Disulfide Isomerase (PDI) antibody (RL90) (ab2792)
(Abcam, UK) served as Golgi [32], sarcolemma [39,40] and
endoplasmic reticulum (ER) markers [41], respectively. The
secondary antibodies used were gold conjugated goat F(ab)2
anti-rabbit IgG (5 nm) and goat anti- mouse IgG (10 nm) (British
Bio Cell International, UK).
Immunoelectron microscopy
A human rectus femoris muscle biopsy was processed for
immunolabelling of sections as described by Tokuyasu (1986)
[42]. Briefly, the tissue was fixed in 8% formaldehyde in PBS over
night, infiltrated with 2.3 M sucrose, mounted on specimen pins
and frozen by immersion in liquid nitrogen. Ultrathin cryosections
were made in a Leica EM UC6 Ultra Microtome with a
DiATOME diamond knife (DiATOME, Switzerland), thawed
on a drop of methylcellulose/sucrose and mounted on carbon
coated Formvar films on copper grids. Sections were rehydrated in
double-distilled water (dsH2O) for 30 min followed by blocking
with 1% Cold Water Fish Skin Gelatine (CWFSG) (Sigma G-
7765). Immunolabelling was performed according to Griffiths
(1993) [43]. For double immunolabelling of FKRP and sub-
cellular markers specific to, either Golgi, ER or sarcolemma,
sections were incubated with mixtures of primary antibodies at the
optimal dilutions determined by single labelling titration experi-
ments. Subsequently after rinsing with PBS, the sections were
incubated with a mixture of the appropriate colloidal gold
conjugated antibodies. Following rinsing with PBS the specimens
were fixed in glutaraldehyde, washed with dsH2O and contrasted
with methylcellulose and uranyl acetate (9:1). The specimens were
examined with a Jeol 1010 Transmission Electron Microscope
(JEOL Ltd., Japan) and micrographs were taken with a Morada
Camera system (Olympus Soft Imaging Solutions, Germany).
The following double labelling experiments were performed on
human muscle sections: i) Rabbit anti-FKRP (FKRP207/208)/
mouse anti-MG160, ii) rabbit anti-FKRP (FKRP207/208)/mouse
anti-ß-dys, iii) rabbit anti-FKRP (FKRP207/208)/mouse anti-
PDI. Secondary antibodies used in these experiments were goat
anti-rabbit, 5 nm gold, in combination with goat anti-mouse,
10 nm gold. To check for possible secondary antibody cross
reactivity, control labelling experiments were carried as above, but
omitting one of the primary antibodies as follows: i) Rabbit anti-
FKRP (FKRP207/208). ii) Mouse anti- MG160. Secondary
antibodies used were the combination of goat anti-rabbit, 5 nm/
goat anti-mouse, 10 nm, as described above.
Pairwise yeast two-hybrid assay
The coding sequence for amino acids 32-494 of human FKRP
(hFKRP) (GenBank accession number GI: 209574324; NM_
001039885.2) was amplified with primers p5 and p3 (Table S1)
and cloned into the bait vector pB27 in-frame with the coding
sequence of the LexA DNA binding domain (DBD); pB27 (N-
LexA-FKRP32-494-C). pB27 is derived from the original
pBTM116 [44]. FKRP amino acids 1–31, thought to contain a
trans-membrane domain [26], were omitted as they were
suspected to conflict with the yeast two-hybrid assay. By using
the SfiI restriction sites on both sides of the bait, the coding
sequence for amino acids 32-494 of FKRP32-494 was transferred
from the original bait vector pB27 into prey plasmid pP7, in frame
with the Gal4 activation domain (AD); pP7 (N-GAL4-FKRP32-
494-C). pP7 is derived from the original pGADGH [45]. The
correct sequences of the DBD and AD constructs were verified by
DNA sequencing with primers as shown in Table S1. FKRP32-
494 – FKRP32-494 interaction was tested by co-transformation of
the constructs in yeast diploid cells, which were obtained using a
mating protocol with L40DGal4 (mata) and Y187 (mata) yeast
strains [46]. Interaction pairs were tested in duplicate as two
independent clones from separate co-transformations. For each
interaction, four different dilutions (10
21–10
24) of the diploid
yeast cells, normalised at 5610
4 cells, were spotted on selective
media. The DO-2 selective medium lacking tryptophan (Trp) and
leucine (Leu) was used as a growth control and to verify the co-
transformation of bait and prey plasmids. The DO-3 selective
medium lacking Trp, Leu and histidine (His) was used to assess
FKRP32-494 – FKRP32-494 interaction. Appropriate negative
controls included combinations of empty bait and prey plasmids,
bait plasmid with FKRP32-494 in combination with empty prey
plasmid and vice versa. The combination of human Smad3 as bait
(GI: 5174512, aa 1–425) and Human Smurf1 as prey (GI:
31317291, aa 150–325, p. N272S, p. F308Y) served as positive
control. The yeast two hybrid experiments were carried out in
collaboration with Hybrigenics SA services, Paris, France.
Construction of FKRP expression plasmids
The complete coding sequence of FKRP, which is contained in
exon 4 of the FKRP gene, was PCR amplified from human
genomic DNA using primers FKRP 1F and FKRP 1R and
subsequently re-amplified with nested primers FKRPOFTO and
FKRPOR (Table S1). High fidelity PrimeSTAR Takara HS DNA
polymerase (Takara Bio Inc., Japan) was used for all PCR based
cloning experiments. The resulting PCR fragment was direction-
ally inserted in conjunction with the CMV promoter of expression
plasmid pcDNA3.1D/V5-His-Topo, and subsequently trans-
formed into One Shot TOP10 chemically competent E. coli
(pcDNA3.1 Directional TOPO Expression Kit) (Invitrogen, USA).
Plasmid DNA was purified with either QIAprep Spin Miniprep
Kit, Qiagen Plasmid Midi Kit (QIAGEN, Sweden) or NucleoBond
Xtra Midi (Marchery-Nagel, Germany), according to manufac-
turer’s specifications. The pcDNA3.1-FKRP expression clone was
used as template for further PCR based cloning of FKRP
truncation mutants, the generation of FKRP-HA and FKRP-
Myc C-terminal fusion proteins and to create FKRP amino acid
substitutions. FKRP C-terminal truncation mutants were gener-
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FKRPOF/FKRP-282 and FKRPOF/FKRP-157. FKRP with C-
terminal HA and Myc fusions were generated by PCR
amplification with primer combinations FKRPOF/FKRP-HA
and FKRPOF/FKRP-Myc (Table S1). Resulting PCR fragments
were cloned into expression vector pcDNA3.1 by the use of
pcDNA3.1/V5-His TOPO TA Expression Kit (Invitrogen, USA)
followed by transformation and plasmid DNA purification as
explained above. In all the above cloning experiments FKRP DNA
inserts contained their own translation termination codons (TGA),
to prevent translational fusion with the downstream V5-His tags.
FKRP CysRSer and AsnRGln amino acid substitutions were
generated directly from pcDNA3.1-FKRP plasmid DNA by site
directed in vitro mutagenesis with primer combinations FKRP-C6S
F/FKRP-C6S R, FKRP-C168S F/FKRP-C168S R, FKRP-
C191S F/FKRP-C191S R, FKRP-C289S F/FKRP-C289S R,
FKRP-C296S F/FKRP-C296S R, FKRP-C317S/C318S F/
FKRP-C317S/C318S R, FKRP-C375S F/FKRP-C375S R,
FKRP-Q172N F/FKRP-Q172N R, FKRP-Q209N F/FKRP-
Q209N R as displayed in Table S1. In vitro mutagenesis was
carried out using QuickChange Site-Directed Mutagenesis Kit
reagents according to manufacturer’s specifications (Stratagene,
USA). Subsequent to all cloning and in vitro mutagenesis,
verification of correct insert orientation and FKRP sequence was
performed by DNA sequencing using flanking and internal
sequencing primers as shown in Table S1. Sequencing reactions
were carried out with BigDye 3.1 kit reagents (Applied Biosystems,
USA). These were separated and detected on an automated
sequencer unit (3130xl, Applied Biosystems/Hitachi, USA) and
further analysed using the SeqScape v2.5 software (Applied
Biosystems, USA).
Cell culture, transfection and preparation of lysates
African green monkey kidney cells (COS-7) (ATCC: CRL-1651)
and Syrian Baby Hamster kidney cells (BHK-21) (ATCC: CCL-
10) were used in transfection experiments. COS-7 cells were
cultured in Dulbecco’s Modified Eagle medium supplemented
with GlutaMAX (GIBCO, USA), D-glucose (4.5 mg/ml) and 10%
Fetal Bovine Serum (FBS) (GIBCO, USA). BHK-21 cells were
cultured in Minimum Essential Medium with Earle’s Salts,
Glutamax with 5% FBS (GIBCO, USA). Both media were
supplemented with 60 U/ml penicillin-G and 60 mg/ml strepto-
mycin (GIBCO, USA). The cells were cultured in 6-well plates and
grown to 80–90% confluence prior to transfection. Each well was
transfected with 2 mg of plasmid DNA of each expression construct
using FuGene HD transfection reagent (Roche, Germany) in Opti-
MEM (GIBCO, USA). The cells were harvested after 48 hrs of
incubation using Mammalian Protein Extraction Reagent (M-
PER, PIERCE, USA) supplemented with Complete Mini EDTA-
free protease inhibitor cocktail (Roche, Germany). Whenever
stated, the extraction reagent was supplemented with 5 mM N-
ethylmaleimide (NEM) (Sigma, Germany). The lysates were
cleared by centrifugation at 140006g for 15 min and protein
concentrations were measured by using DC Protein assay kit
(BioRad, USA) and a Heigar THERMOMAX Microplate reader.
For protein cross-linking 10 mM Ethylene glycol-bis(Succini-
midylSuccinate) (EGS) (PIERCE, USA) was added immediately to
the cleared lysate followed by incubation at room temperature
(RT), for 30 min. The reaction was quenched with 35 mM Tris,
pH 7.5, for 15 min.
SDS Page and Western blot analysis
Prior to Sodium Dodecyl Sulfate-Polyacrylamide Gel Electro-
phoresis (SDS-PAGE) protein samples were added LDS loading
buffer as recommended by the supplier (Invitrogen, USA). For
reducing gel electrophoresis NuPAGE Sample Reducing agent
(106) (Invitrogen, USA) was added to 16followed by incubation
at 99uC for 5 min or, alternatively, samples were reduced by
adding 300–400 mM Dithiothreitol (DTT) (Sigma, Germany),
followed by incubation at RT for 30 min. Samples were loaded
onto NuPage Novex Bis-Tris 4–12% polyacrylamide gels (Invitro-
gen, USA). After separation the gel proteins were electrotrans-
ferred onto PVDF membranes that were subsequently blocked
with 0.1% Tween Phosphate buffered saline (PBST) containing
5%, fat free, dry milk. After incubation with primary and
secondary antibodies, membranes were developed by Tropix
CDP-star (Applied Biosystems, USA). Immunoreactive bands were
visualised using a FUJIFILM Luminescent Image Analyzer LAS-
3000 (Fuji photo film, Co., LTD, Japan).
Co-Immune precipitation
Co-immune precipitation was performed using the ProFound
Mammalian c-Myc Tag IP/Co-IP Kit (PIERCE, USA). Briefly,
clarified cell lysates supplemented with 5 mM NEM and protease
inhibitor, containing 600 mg of total protein, were pre-incubated
with agarose coupled anti-myc antibody at 4uC for 45 minutes.
Subsequent to three washing steps proteins were eluted in 60 ml
26 Non-reducing sample buffer under denaturing conditions
(5 min at 99uC). Eluted proteins were subjected to SDS-PAGE at
reducing condition followed by Western blot analysis.
Deglycosylation
Lysates (8–20 mg of protein), prepared from BHK-21 or COS-7
cells transfected with pcDNA3.1-FKRP, were treated with 106
glycoprotein denaturing buffer for 10 min, at 100uC, and then
incubated with 1500 units of Endoglycosidase H (Endo H)
(NewEngland BioLabs) or 750 units of N-Glycosidase F (PNGase
F) (New England BioLabs) for one hour at 37uC.
Supporting Information
Table S1 List of primers used for PCR amplification, in
vitro mutagenesis, generation of fusion proteins and
DNA sequencing. All primers are shown in 59to 39direction.
Sequences that encode HA or Myc tags are shown in bold. Stop
codons introduced in reverse primers (R) are underlined.
Nucleotides introduced for site directed mutagenesis are under-
lined. SpeI and PacI restriction sites are shown in lower case.
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